Each has a different evidence base KPV with limited human data on inflammatory bowel conditions, Semax with a longer history of use in Russia for cognitive and stroke-recovery indications
However, their capacity to cross the BBB varies substantially across compounds and is influenced by a combination of molecular weight, hydrophilicity, protein binding, susceptibility to enzymatic degradation, and structural modifications [66]
[1] [3] This means it activates both the GIP receptor and the GLP-1 receptor simultaneously, making it pharmacologically distinct from traditional GLP-1 agonists
Of course when they gain it all back which easily 90% will do ( and we would see that if somebody had the balls to measure with DEXAs 2,3 or 4 years after cessation) of course their comorbidities will return
In Phase II , the liver needs to neutralize those "shards" so they can be safely removed from the body